Bile Acid Pathways Reduce Liver Fat in Preclinical Mouse Study

Bile Acid Treatment Clears Hepatic Fat in Mice

A bile acid called hyodeoxycholic acid (HDCA) prevented excess fat from building up in the livers of mice fed a high-fat diet. Researchers at Chiba University in Japan and the University of Cambridge in the United Kingdom published the findings in the journal Cell Reports.

The investigators discovered the compound after noticing that adipose tissue transplantation raised circulating HDCA levels in diabetic mice. When administered at a 0.25 percent dose, HDCA decreased liver triglycerides, lowered blood glucose, and improved liver function markers.

These metabolic improvements occurred without any change in the animals' total body weight. This outcome indicates that the reduction in liver fat did not stem from weight loss.

Two Distinct Signaling Pathways Drive Fatty-Acid Breakdown

Hyodeoxycholic acid stops fat accumulation by stimulating peroxisome proliferator-activated receptor alpha (PPARα), a regulatory protein that controls fatty-acid oxidation (FAO). In test mice that lacked PPARα, HDCA failed to prevent hepatic steatosis.

The study mapped two independent pathways through which the bile acid activates this target protein. First, HDCA increased invariant natural killer T (iNKT) cells in the liver, which produced interferon-gamma (IFN-γ) to activate PPARα and switch on fat-burning genes.

Second, HDCA raised circulating levels of glucagon-like peptide-1 (GLP-1), a gut hormone that regulates energy metabolism. In mice lacking the GLP-1 receptor, HDCA could no longer clear excess liver triglycerides.

Testing GLP-1 Receptor Activity Independent of Immune Cells

The researchers injected liraglutide, an approved diabetes drug that activates the GLP-1 receptor, to clarify how the hormone interacts with liver tissue. Liraglutide reduced liver fat in standard mice and in mice lacking iNKT cells.

Liraglutide failed to reduce fat accumulation in mice lacking the GLP-1 receptor or PPARα. This finding confirmed that GLP-1 signaling clears hepatic triglycerides through PPARα directly, without requiring the immune-cell pathway.

Translational Limits and Clinical Context for MASLD

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects roughly one-quarter of adults globally. Hepatic steatosis represents the earliest phase of the disease, which can progress to cellular injury, fibrosis, and permanent cirrhosis if left unchecked.

The study clarifies biological mechanisms linking bile acids to metabolic regulation, but the evidence comes strictly from an animal model. HDCA is an investigational molecule in this context, not an approved medical treatment for patients with MASLD.

Individuals reviewing elevated liver enzymes or metabolic blood panels should consult a licensed clinician about established lifestyle and medical strategies.